Item 2.02. Results of Operations and Financial Condition.
On January 27, 2022 we issued the press release furnished as Exhibit 99.1. The
press release describes the results of our operations for the quarter ended
December 31, 2022.
The information furnished in this Current Report on Form 8-K under Item 2.02 and
the attached exhibit shall not be deemed "filed" for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
Item 8.01. Other Events.
On January 27, 2022 we announced that our board of directors declared a
quarterly cash dividend of US $0.42 per share. The dividend will have a record
date of February 10, 2022, payable on March 17, 2022. The dividend will be paid
in U.S. currency to holders of ResMed's common stock trading on the New York
Stock Exchange. Holders of CHESS Depositary Instruments trading on the
Australian Securities Exchange will receive an equivalent amount in Australian
currency, based on the exchange rate on the record date, and reflecting the 10:1
ratio between CDIs and NYSE shares. The ex-dividend date will be February 9,
2022 for common stockholders and for CDI holders. ResMed has received a waiver
from the ASX's settlement operating rules, which will allow ResMed to defer
processing conversions between its common stock and CDI registers from
February 9, 2022 through February 10, 2022, inclusive.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibits: Description of Document
99.1 Press Release dated January 27, 2022 regarding results of
operations
104 Cover Page Interactive Data File (embedded within the Inline XBRL,
document)
-2-
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
RESMED, INC. 
